Pharmaceutical Chamber queries controversial drug imports

Colombo (News 1st) – The Sri Lanka Chamber of the Pharmaceutical Industry (SLCPI) has raised concerns over media and social media reports stating that the Minister of Health obtained cabinet approval to purchase a large number of pharmaceutical products for use in the health sector from two manufacturers in India on an urgent basis. 

It highlighted that the reports specifically stated that neither the manufacturing sites nor the products to be purchased are registered with the National Medicines Regulatory Authority (NMRA), which is the sole and final authority that determines what pharmaceuticals are to be imported and used in the country. 

In a letter addressed to the NMRA, the SLCPI quoted news reports stating that the Health Minister had personally visited India in relation to procuring these products and the agreement has been finalized.

“Such actions give rise to serious concerns in the industry and sets a dangerous precedent,” the SLCPI stated.

It also questioned whether such actions were in line with the NMRA Act of 2015.

The Sri Lanka Chamber of the Pharmaceutical Industry sought clarification regarding the media reports and raised its objections against such actions if it is true.

See letter below:

Latest News

No Byline Policy

Editorial Guidelines

Corrections Policy

Source